I am a transplantsurgeon with a special interest in recurrence of disease after kidney or kidney-pancreas transplantation.
Our other major interest is the treatment of children with focal segmental glomerulosclerosis (FSGS) and the problematic recurrence of proteinuria after kidney transplant. Ou group initiated a protocol utilizing one dose of rituximab in addition to the standard induction immunosuppression protocol for pediatric patients with FSGS in order to mitigate against the recurrence of proteinuria after kidney transplantation.
These two areas of research represent robust examples of “bedside to bench and back again’‘ translational research.